These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 10027919

  • 1. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH.
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis.
    Hirata M, Katsumata K, Masaki T, Koike N, Endo K, Tsunemi K, Ohkawa H, Kurokawa K, Fukagawa M.
    Kidney Int; 1999 Dec; 56(6):2040-7. PubMed ID: 10594779
    [Abstract] [Full Text] [Related]

  • 4. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Jun; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 8. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism.
    Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y.
    Am J Kidney Dis; 2000 Mar; 35(3):458-64. PubMed ID: 10692271
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
    Li X, Yu L, Asuncion F, Grisanti M, Alexander S, Hensley K, Han CY, Niu QT, Dwyer D, Villasenor K, Stolina M, Dean C, Ominsky MS, Ke HZ, Tomlinson JE, Richards WG.
    Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.
    Neves KR, Graciolli FG, dos Reis LM, Pasqualucci CA, Moysés RM, Jorgetti V.
    Kidney Int; 2004 Dec; 66(6):2237-44. PubMed ID: 15569312
    [Abstract] [Full Text] [Related]

  • 13. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women.
    Zella JB, Plum LA, Plowchalk DR, Potochoiba M, Clagett-Dame M, DeLuca HF.
    Am J Nephrol; 2014 Dec; 39(6):476-83. PubMed ID: 24854296
    [Abstract] [Full Text] [Related]

  • 14. Hyperphosphatemia modestly retards parathyroid hormone suppression during calcitriol-induced hypercalcemia in normal and azotemic rats.
    Jara A, Chacón C, Felsenfeld AJ.
    Nephron; 2002 Dec; 92(4):883-8. PubMed ID: 12399635
    [Abstract] [Full Text] [Related]

  • 15. Zinc nutritional status modifies renal osteodystrophy in uremic rats.
    Kimmel PL, Langman CB, Bognar B, Faugere MC, Chawla LS, Watkins DW, Malluche HH.
    Clin Nephrol; 2001 Dec; 56(6):445-58. PubMed ID: 11770796
    [Abstract] [Full Text] [Related]

  • 16. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Dec; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 17. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.
    Geng Z, Monier-Faugere MC, Bauss F, Malluche HH.
    Clin Nephrol; 2000 Jul; 54(1):45-53. PubMed ID: 10939756
    [Abstract] [Full Text] [Related]

  • 18. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ.
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [Abstract] [Full Text] [Related]

  • 19. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.
    Murakami K, Miyachi H, Watanabe A, Kawamura N, Fujii M, Koide S, Murase M, Kushimoto H, Hasegawa M, Tomita M, Hiki Y, Sugiyama S.
    Clin Exp Nephrol; 2004 Jun; 8(2):134-8. PubMed ID: 15235930
    [Abstract] [Full Text] [Related]

  • 20. Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism.
    Sanchez CP, He YZ.
    J Am Soc Nephrol; 2005 Apr; 16(4):929-38. PubMed ID: 15728789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.